| bDMARD ≤6 months after ABA discontinuation | bDMARD prior to initial ABA treatment in pts who restarted ABA |
---|
|
---|
| Biologic naïve | Biologic failure | Biologic failure |
---|
|
---|
| n=186 | n=526 | n=186 |
---|
|
---|
None | 35 (18.8) | 86 (16.3) | |
Abatacept | 77 (41.4) | 186 (35.4) | – |
IV | 71 (38.2) | 170 (32.3) | |
SC | 6 (3.2) | 16 (3.0) | |
TNFi | 41 (22.0) | 74 (14.1) | 181 (97.3) |
Adalimumab | 10 (5.4) | 12 (2.3) | 108 (58.1) |
Etanercept | 13 (7.0) | 21 (4.0) | 125 (67.2) |
Infliximab | 7 (3.8) | 13 (2.5) | 55 (29.6) |
Certolizumab | 7 (3.8) | 17 (3.2) | 5 (2.7) |
Golimumab | 4 (2.2) | 11 (2.1) | 2 (1.1) |
Other bDMARD | 33 (17.7) | 180 (34.2) | 51 (27.4) |
Anakinra | 1 (0.5) | 4 (0.8) | 5 (2.7) |
Rituximab | 6 (3.2) | 58 (11.0) | 30 (16.1) |
Tocilizumab | 26 (14.0) | 118 (22.4) | 21 (11.3) |
Data are n (%) |